Quick Answer
RHYTHM PHARMACEUTICALS, INC. reported Total Revenue of $189.76 million for fiscal year 2025.
RHYTHM PHARMACEUTICALS, INC. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $189.76M +45.8% |
$130.13M +68.1% |
$77.43M +227.6% |
$23.64M | — | — |
| Revenue (ASC 606) | $189.76M +45.8% |
$130.13M +68.1% |
$77.43M +227.6% |
$23.64M | — | — |
| Net Income | -$196.54M +24.6% |
-$260.60M -41.1% |
-$184.68M -2.0% |
-$181.12M -160.2% |
-$69.61M +48.0% |
-$134.00M +4.8% |
| Diluted EPS | -$3.11 +28.3% |
-$4.34 -35.6% |
-$3.20 +7.8% |
-$3.47 -147.9% |
-$1.40 +53.9% |
-$3.04 +21.2% |
| Total Assets | $480.20M +22.4% |
$392.27M +17.9% |
$332.75M -13.0% |
$382.48M +16.1% |
$329.52M +76.1% |
$187.07M -39.4% |
| Cash and Equivalents | $54.30M -39.1% |
$89.14M +48.4% |
$60.08M -52.9% |
$127.68M +115.5% |
$59.25M -41.3% |
$100.85M +61.9% |
| Long-Term Debt | $100.89M -6.8% |
$108.27M +2.0% |
$106.14M | — | — | — |
| Stockholders Equity | $139.07M +540.0% |
$21.73M -87.2% |
$169.76M -35.8% |
$264.26M -7.0% |
$284.15M +70.6% |
$166.53M -40.7% |
| R&D Expense | $167.34M -29.7% |
$237.96M +76.3% |
$134.95M +24.2% |
$108.63M +4.3% |
$104.13M +15.1% |
$90.45M -17.4% |
| Operating Income | -$192.02M +27.7% |
-$265.50M -44.0% |
-$184.36M -2.9% |
-$179.16M -5.3% |
-$170.06M -24.5% |
-$136.57M +6.5% |
| Shares Outstanding | 67.21M +7.7% |
62.39M +5.0% |
59.43M +5.0% |
56.61M +12.6% |
50.28M +13.7% |
44.24M +0.5% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $51.30M | +54.3% | +5.8% |
| Revenue (ASC 606) | September 30, 2025 | $51.30M | +54.3% | +5.8% |
| Net Income | September 30, 2025 | -$52.90M | -21.2% | -13.4% |
| Diluted EPS | September 30, 2025 | -$0.82 | -12.3% | -9.3% |
| Total Assets | September 30, 2025 | $506.87M | +39.4% | +36.0% |
| Cash and Equivalents | September 30, 2025 | $52.08M | +9.6% | -61.6% |
| Long-Term Debt | September 30, 2025 | $103.41M | — | -2.5% |
| Stockholders Equity | September 30, 2025 | $148.82M | +1226.9% | +1349.7% |
| R&D Expense | September 30, 2025 | $46.03M | +21.3% | +8.8% |
| Operating Income | September 30, 2025 | -$52.65M | -20.0% | -16.2% |
| Shares Outstanding | September 30, 2025 | 66.68M | +8.5% | +4.3% |
- RHYTHM PHARMACEUTICALS, INC. reported Total Revenue of $189.76 million for fiscal year 2025.
- RHYTHM PHARMACEUTICALS, INC. showed an increase of +45.8% in Total Revenue compared to the prior fiscal year.
- RHYTHM PHARMACEUTICALS, INC. reported Revenue (ASC 606) of $189.76 million for fiscal year 2025.
- RHYTHM PHARMACEUTICALS, INC. showed an increase of +45.8% in Revenue (ASC 606) compared to the prior fiscal year.
- RHYTHM PHARMACEUTICALS, INC. reported Net Income of -$196.54 million for fiscal year 2025.
- RHYTHM PHARMACEUTICALS, INC. showed an increase of +24.6% in Net Income compared to the prior fiscal year.
- RHYTHM PHARMACEUTICALS, INC. reported Diluted EPS of $3.11 per share (loss) for fiscal year 2025.
- RHYTHM PHARMACEUTICALS, INC. showed an increase of +28.3% in Diluted EPS compared to the prior fiscal year.
- RHYTHM PHARMACEUTICALS, INC. reported Total Assets of $480.20 million for fiscal year 2025.
- RHYTHM PHARMACEUTICALS, INC. showed an increase of +22.4% in Total Assets compared to the prior fiscal year.
- RHYTHM PHARMACEUTICALS, INC. reported Cash and Equivalents of $54.30 million for fiscal year 2025.
- RHYTHM PHARMACEUTICALS, INC. showed a decrease of -39.1% in Cash and Equivalents compared to the prior fiscal year.
- RHYTHM PHARMACEUTICALS, INC. reported Long-Term Debt of $100.89 million for fiscal year 2025.
- RHYTHM PHARMACEUTICALS, INC. showed a decrease of -6.8% in Long-Term Debt compared to the prior fiscal year.
- RHYTHM PHARMACEUTICALS, INC. reported Stockholders Equity of $139.07 million for fiscal year 2025.
- RHYTHM PHARMACEUTICALS, INC. showed an increase of +540.0% in Stockholders Equity compared to the prior fiscal year.
- RHYTHM PHARMACEUTICALS, INC. reported R&D Expense of $167.34 million for fiscal year 2025.
- RHYTHM PHARMACEUTICALS, INC. showed a decrease of -29.7% in R&D Expense compared to the prior fiscal year.
- RHYTHM PHARMACEUTICALS, INC. reported Operating Income of -$192.02 million for fiscal year 2025.
- RHYTHM PHARMACEUTICALS, INC. showed an increase of +27.7% in Operating Income compared to the prior fiscal year.
- RHYTHM PHARMACEUTICALS, INC. reported Shares Outstanding of 67.21 million shares for fiscal year 2025.
- RHYTHM PHARMACEUTICALS, INC. showed an increase of +7.7% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: